South Africa's Tutu back in hospital after surgery
- Deutsche helps lift European stocks before Yellen, Draghi
- BlackBerry (BBRY) Tops Q2 EPS by 5c; Will End Internal Hardware Development; Boosts FY17 Outlook
- Nike (NKE) Tops Q1 EPS by 17c; Futures Orders Miss Views
- Oil climbs after industry data shows U.S. inventory draw
- Tempur Sealy (TPX) Updates on Outlook; Sees Q3 Sales Below Prior Expectations
The former Anglican archbishop of Cape Town Desmond Tutu waits to receive the 2013 Templeton Prize at the Guildhall in central London in this file photo dated May 21, 2013. REUTERS/Paul Hackett/File Photo
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
CAPE TOWN (Reuters) - South African cleric and anti-apartheid icon Desmond Tutu was readmitted to hospital on Saturday to treat an infection following a surgery last week, his family said.
Tutu, the former Anglican archbishop of Cape Town, was discharged from hospital on Wednesday after a successful surgery to treat recurring infections that have afflicted him in the past.
"The archbishop underwent the surgical procedure 10 days ago to address the cause of recurring infections resulting from past treatment received for prostate cancer," the family said in a brief statement.
"The archbishop was readmitted on Saturday as a precaution after his surgical wound had shown signs of infection."
The 84-year-old Nobel Peace Prize winner spoke against white-minority rule from his pulpit, earning him global acclaim.
(Writing by Olivia Kumwenda-Mtambo Editing by Jeremy Gaunt.)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Germany denies preparing Deutsche Bank rescue plan
- Special Report: Flawed CDC report left Indiana children vulnerable to lead poisoning
- Iraqi minister's downfall hurts prospect for financial bailout
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!